Ipca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 26838.10 Crore) operating in Pharmaceuticals sector.
Ipca Laboratories Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue, Export Incentives and Sale of services for the year ending 31-Mar-2021.
Financials
For the quarter ended 30-09-2021, the company reported a Consolidated Total Income of Rs 1562.51 Crore, down -1.53 % from last quarter Total Income of Rs 1586.81 Crore and up 13.51 % from last year same quarter Total Income of Rs 1376.55 Crore. Company reported net profit after tax of Rs 257.73 Crore in latest quarter.
Investment Rationale
The brokerage retains Dec’22 TP of Rs2,240, which implies a 22x P/E on Dec’23E EPS. Upside risks: better-than-expected export growth, resolution of US FDA import alert and a decline in raw material prices. Downside risks: lower-than-expected growth and slowdown in IPM
Promoter/FII Holdings
Promoters held 46.29 per cent stake in the company as of 30-Sep-2021, while FIIs owned 18.46 per cent, DIIs 25.24 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
